Flexion Therapeutics names first chief business officer

Arthur Fratamico takes up the role

Arthur Fratamico has joined US drug developer Flexion Therapeutics as its first chief business officer. He has more than 13 years of business development experience with emerging biopharmaceutical companies.

Prior to joining Flexion, Fratamico led the business development efforts for Trevena, Gemin X Pharmaceuticals and MGI Pharma.

Flexion is a developer of therapeutics for musculoskeletal disorders. The firm is currently advancing a portfolio of drug candidates that have the potential to treat osteoarthritis.

You may also like

Research & Development

Flexion Therapeutics signs agreements with four pharmaceutical firms

Flexion Therapeutics, a US developer of drug candidates, has signed agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and has gained funding from Pfizer.
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now